Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Evotec SENASDAQ: EVO

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of €38.73M (cash outflow) rose 84.3% year over year, behind the +161.7% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 19.6% of revenue in FY2025, down 6.1 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +84.3% toward the trailing-twelve-month pace of +161.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€38.73M-115.9% QoQ
Last fiscal yearDec 2025
€148.32M+172.5% YoY
LTMMar 2026
€99.46M+161.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.3%——
1 year+172.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

EUR · from the cash flow

Latest · FY2025
148.32M EUR
Year-over-year change
+172.5%
4-year CAGR
-14.4%

Net Change in Cash vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +161.7% is the 6th highest of 11, against a peer median of +93.3%.
  • Net change in cash amounts to 13.3% of revenue for EVO, versus a peer median of 15.8%.
EVO Competitors
Net Change in Cash for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$442.59M USD-563.9%—17.6%
PCRXPacira BioSciences, Inc.LTM Mar 2026$139.3M USD-239.9%-37.4%19.0%
EVOEvotec SELTM Mar 2026€99.46M EUR+161.7%—13.3%
AZTAAzenta, Inc.LTM Sep 2026$98.37M USD+304.7%-34.9%15.8%
SDGRSchrödinger, Inc.LTM Sep 2026$72.13M USD+516.7%—26.8%
TLRYTilray Brands, Inc.LTM Feb 2026$66.56M USD-9.8%-53.6%5.6%
PHVSPharvaris N.V.LTM Sep 2026€52.24M EUR-316.8%——
NVCRNovoCure LimitedLTM Mar 2026$32.11M USD-90.2%-12.6%4.8%
HROWHarrow Health, Inc.LTM Mar 2026$27.92M USD+1640.7%-22.0%10.4%
ALVOAlvotechLTM Mar 2026$25.29M USD+196.3%+35.3%4.5%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$17.83M USD+366.8%—19.7%
Peer median (excluding EVO) —+93.3%-28.5%15.8%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.